Synopsys heads into its May 27 earnings report with options positioning notably more constructive than its recent norm — a clear break from the cautious stance that dominated the past month.
The clearest signal is in the put/call ratio. It has dropped to 0.90, more than one standard deviation below its 20-day average of 1.04, meaning traders have rotated away from the defensive hedges that were piling up through early May, when the PCR briefly touched its 52-week high of 1.21. The shift is striking: as recently as May 8, puts were running significantly heavier than calls; by this week, that protection has been actively unwound. Borrow conditions reinforce the benign backdrop — short interest has eased roughly 10% over the past month to 2.4% of free float, cost to borrow is a negligible 0.43%, and availability is effectively unconstrained. There is no meaningful pressure building in the lending market.
The stock has rallied to meet that positioning. Shares closed at $534.56 on Tuesday, up more than 8% on the week and 6.7% over the past month, and are now trading just below Rosenblatt's freshly raised target of $575. Closest peer Cadence Design Systems gained a similar 10.3% on the week, suggesting broad EDA sector tailwinds rather than SNPS-specific momentum. also rallied hard (+9.6% on the week), while lagged noticeably at -1.8%, highlighting that the bid has been concentrated in AI-adjacent software names.
The analyst picture has tilted positive heading into the print. Rosenblatt raised its target to $575 on the morning of earnings day, keeping its Buy. Citigroup lifted to $600 earlier in May, also maintaining Buy. Wells Fargo raised its target to $505 from $450, though it remains at Equal-Weight — a signal that even the sideliners are acknowledging upward estimate drift. The bull case centres on Synopsys's position at the intersection of AI-driven chip design complexity and accelerating EDA adoption, with margin improvement expected from recent cost discipline. Bears point to Intel customer concentration, rising in-house design activity among large fabless players, and China export restrictions that cap one of the company's key growth markets. Morgan Stanley's downgrade to Equal-Weight in late February — cutting its target to $480 from $550 — remains the most prominent dissenting voice, though the stock has since recovered well past those levels, partially undermining the bear thesis on price action alone.
Historical reactions offer a mixed guide. The most recent print on April 16 produced a clean +2.5% one-day move and a +4.2% five-day drift. Before that, two consecutive reports delivered declines of 3–5% on the day. The mean analyst target of $541 sits just above the current price of $534, leaving limited implied upside from consensus — which means the earnings report is less a referendum on whether Synopsys can grow and more a test of whether the AI chip design narrative can justify a valuation running at roughly 34x earnings and 25x EV/EBITDA after a strong recovery rally.
See the live data behind this article on ORTEX.
Open SNPS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
